Document resource
Background and Importance Patients in haemato-oncology are at high risk of severe infections due to neutropenia, immune deficiencies, and the use of invasive devices. Irregular availability of essential antibiotics compromises both the speed and standardisation of treatment.Aim and Objectives This study examines the effectiveness of a priority dispensing algorithm to strengthen therapeutic continuity and patient safety.Material and Methods A prospective quasi-experimental study was conducted over eight weeks (May–June 2025) in the haemato-oncology department . Antibiotics were classified by criticality (essential, important, reserve). A decision-making dispensing algorithm was developed, including alternatives in case of shortages and standardised dosing. The algorithm was evaluated using three indicators:Coverage of critical clinical situations;Reduction of dispensing delays (>2 hours);Decrease in non–standardised substitutions.Results Among the 12 antibiotics analysed, 4 (33%) essential drugs were initially out of stock. After implementing the algorithm, coverage of critical clinical situations reached 100%. The average dispensing time decreased from 3.5 hours to 1.2 hours ( p < 0.05), and the rate of unvalidated substitutions dropped from 18% to 4%. Pharmacists also reported a 40% improvement in traceability and a significant reduction in potential dispensing errors.Conclusion and Relevance The prioritised dispensing algorithm proved to be an effective tool to improve patient safety in haemato-oncology, standardise antibiotic dispensing, and reduce the impact of drug shortages. Its integration into pharmacy practice could serve as a model for other high-risk infectious disease units.References and/or Acknowledgements 1. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):e56–93.2. European Society for Medical Oncology (ESMO). Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2022;33(12):1213–24.Conflict of Interest No conflict of interest